| 10.0204 0 (0%) | 03-27 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 379.93 | 1-year : | 420.63 |
| Resists | First : | 325.28 | Second : | 360.13 |
| Pivot price | 296.71  |
|||
| Supports | First : | 268.92 | Second : | 223.74 |
| MAs | MA(5) : | 279.34 |
MA(20) : | 304.7 |
| MA(100) : | 320.86 |
MA(250) : | 346.4 |
|
| MACD | MACD : | -15.2 |
Signal : | -12.4 |
| %K %D | K(14,3) : | 11.5 |
D(3) : | 14.6 |
| RSI | RSI(14): 28.7  |
|||
| 52-week | High : | 473.5 | Low : | 261.58 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BIO ] has closed above bottom band by 26.6%. Bollinger Bands are 170.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 14 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 278.19 - 280.06 | 280.06 - 281.61 |
| Low: | 268.85 - 270.68 | 270.68 - 272.2 |
| Close: | 272.91 - 275.89 | 275.89 - 278.36 |
The investment seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the NASDAQ Biotechnology Index®. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
Thu, 25 Apr 2019
Politics Weigh On Health Care ETFs | etf.com - etf.com
Tue, 30 Jan 2018
The Stealth Marijuana Play In Your ETF - etf.com
Tue, 26 Dec 2017
Worst Performing ETFs Of 2017 | etf.com - etf.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 23 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 15.2 (%) |
| Held by Institutions | 81.6 (%) |
| Shares Short | 565 (K) |
| Shares Short P.Month | 503 (K) |
| EPS | -21.82 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 306.51 |
| Profit Margin | -23.9 % |
| Operating Margin | 14.2 % |
| Return on Assets (ttm) | 1.7 % |
| Return on Equity (ttm) | -7 % |
| Qtrly Rev. Growth | -6.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 114 |
| EBITDA (p.s.) | 21.84 |
| Qtrly Earnings Growth | -56.3 % |
| Operating Cash Flow | 375 (M) |
| Levered Free Cash Flow | 171 (M) |
| PE Ratio | -12.72 |
| PEG Ratio | 1.4 |
| Price to Book value | 0.9 |
| Price to Sales | 2.43 |
| Price to Cash Flow | 17.33 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|